Scarica l'app Stockscreener
168.50
1.91%
-3.275
Dopo l'orario di chiusura:
168.51
0.005
+0.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$171.78
Aprire:
$171.22
Volume 24 ore:
616.86K
Relative Volume:
0.91
Capitalizzazione di mercato:
$8.62B
Reddito:
$638.50M
Utile/perdita netta:
$-183.17M
Rapporto P/E:
-45.61
EPS:
-3.6943
Flusso di cassa netto:
$-93.89M
1 W Prestazione:
+2.58%
1M Prestazione:
+1.28%
6M Prestazione:
+40.49%
1 anno Prestazione:
+53.54%
Intervallo 1D:
$166.65
$171.22
Intervallo di 1 settimana:
$155.00
$174.81
Portata 52W:
$86.99
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
168.50 | 8.62B | 638.50M | -183.17M | -93.89M | -3.6943 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Iniziato | B. Riley Securities | Buy |
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
AXSM Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Balipodect Licensing Deal From Takeda - Sahm
Element Squared LLC Invests $1.48 Million in Axsome Therapeutics, Inc. $AXSM - marketbeat.com
Axsome Therapeutics Acquisition Play Signals A Bold Push Into Schizophrenia Market! - Smartkarma
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome Acquires Global Rights to TAK-063 from Takeda - intellectia.ai
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $223 - Moomoo
Axsome Therapeutics acquires Takeda’s selective PDE10A inhibitor balipodect - The Pharma Letter
AXSM Technical Analysis & Stock Price Forecast - intellectia.ai
Takeda (TAK) Sells Rights to Schizophrenia Drug to Axsome - GuruFocus
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda - Benzinga
Axsome Therapeutics Acquires Global Rights to Balipodect, a Selective PDE10A Inhibitor, for Schizophrenia and Neuropsychiatric Disorders 1 - minichart.com.sg
Axsome acquires global rights to Takeda’s balipodect - TipRanks
Axsome acquires global rights to balipodect from Takeda By Investing.com - Investing.com Canada
Axsome Therapeutics Acquires Exclusive Global Rights to Balipodect from Takeda - MarketScreener
Axsome Therapeutics acquires balipodect, gains global rights and plans Phase 3-enabling work for schizophrenia - TradingView
Axsome Therapeutics (NASDAQ: AXSM) secures global rights to balipodect - Stock Titan
Axsome Therapeutics Incto Begin Phase 3 Tr - Moomoo
Axsome adds a schizophrenia drug candidate, targets 2026 Phase 3 prep - Stock Titan
Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling - Yahoo! Finance Canada
Dow Update: How does Axsome Therapeutics Inc compare to its peersWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
(AXSM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
Mizuho reiterates Axsome stock Outperform rating on Rx data - Investing.com
Vanguard (AXSM) reports 0 shares after internal realignment - stocktitan.net
Phase 3 trial initiation pushes Axsome Therapeutics stock up amid technical signals of buyer strength - Traders Union
Guggenheim Keeps Their Buy Rating on Axsome Therapeutics (AXSM) - theglobeandmail.com
Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Truist Financial - MarketBeat
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - marketbeat.com
Guggenheim raises Axsome stock price target on Alzheimer’s drug outlook - Investing.com
Axsome Therapeutics, Inc. $AXSM Position Increased by Assenagon Asset Management S.A. - MarketBeat
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
JPMorgan Chase & Co. Has $30.43 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Overview: Is Axsome Therapeutics Inc stock trending bullishTrade Exit Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
AXSM PE Ratio & Valuation, Is AXSM Overvalued - intellectia.ai
Mizuho reiterates Axsome stock Outperform on Auvelity growth By Investing.com - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com
Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation - MSN
Axsome shares slip despite fourth-quarter earnings beat and strong revenue growth - MSN
(AXSM) Risk Channels and Responsive Allocation - Stock Traders Daily
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - AOL.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC - MarketBeat
A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st
Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):